ChromoGenics AB (CHRO-ST) Stock Split, History Data
Working capital analysis
In terms of working capital, ChromoGenics AB maintains a healthy position.
The total current assets of the company are valued at $29758000.
This represents a growth rate of -35.378% compared to the previous year.
Breaking down the current assets, the cash and investments are worth $7926000, exhibiting a growth rate of -67.147% year-on-year.
The receivables, another significant portion of the current assets, are valued at $11658000.
The year-on-year growth rate for receivables is -0.487%.
The inventory, which forms a critical part of the assets, is valued at $10174000.
This represents a healthy year-on-year growth of -0.235%
On the liabilities side, the company's current liabilities total $27362000.
This reflects a growth rate of 10.091% over the previous year, indicating the company's financial obligations are well under control.
2023
2022
2021
2020
2019
2018
Cash and investments
7.93
24.13
18.85
93.39
24.85
7.52
Receavebles
11.66
11.71
13.67
8.65
15.82
3.43
Inventory
10.17
10.20
11.01
8.24
6.75
7.42
Other
9.04
0.06
2.15
1.09
2.59
10.56
Total Current Assets
29.76
46.05
45.69
111.38
50.01
25.50
Acc Payable
2.77
8.61
7.77
8.15
18.46
5.29
Short Term Debt
0.20
0.30
15.43
0.00
1.84
0.00
Other Current Liab
24.39
15.94
3.41
21.40
9.58
31.95
Current Liabilities
27.36
24.85
52.64
29.55
41.69
37.24
Capital Structure
When examining the capital structure of ChromoGenics AB, it is clear that the company manages a robust portfolio.
The value of their total assets clocks in at $139163000.
When juxtaposed with the previous year, this marks a growth rate of -13.831%, showcasing the company's ability to steadily grow its asset base.
Turning to liabilities, the company has total liabilities amounting to $93983000.
Compared to the prior year, this reflects a growth rate of 3.263%.
The long-term debt forms a sizable part of these liabilities, coming in at $66620999.
Over the last year, the long-term debt has grown by 4.449%.
On the asset side, the cash and equivalent reserves are worth $7926000.
The year-on-year growth of these reserves is -67.147%.
The company's common stock, another important asset, holds a value of $35062000, growing at a rate of 22.333% from the previous year.
Finally, the company's retained earnings stand at $-715419000, marking a growth rate of 8.210% year-over-year.
These earnings represent the profits that ChromoGenics AB has chosen to reinvest in the business rather than distribute as dividends.
Total Assets
$139.16
Total liabilities
$93,983,000.00
Long term debt
$66.62
Cash and eqv
$7,926,000.00
Goodwill
$0.00
Retained earnings
-$715,419,000.00
Common stock
$26.52
Enterprise Value
$0.37
Net earnings per share (EPS)
ChromoGenics AB has an EPS of $-20.75, which signifies the profit allocated per share of common stock. With a growth rate of -17.232% this year, it indicates the company's increasing profitability and potential for share value growth. This trend signals robust financial performance and future potential.
Years
Q1
Q2
Q3
Q4
Total
2023
-7.15
-6.91
-2.66
-4.03
-20.75
2022
-0.43
-0.36
-0.26
-16.65
-17.70
2021
-0.34
-1.15
-0.23
-0.5
-2.22
2020
-1.26
-0.96
-0.79
-1.23
-4.24
2019
-5.89
-2.49
-1.47
-6.69
-16.54
2018
-11.87
-7.32
-5.47
-27.18
-51.84
2017
-22.4
-8.41
-9.77
-39.06
-79.64
2016
-27.68
-47.2
-22.9
-71.35
-169.13
2015
-
-
-
-79.55
-79.55
Brief information
ChromoGenics AB (CHRO.ST) stock split history
Understanding the historical stock splits of ChromoGenics AB (CHRO.ST) provides insights into its past financial decisions and investor sentiment. A stock split occurs when a company increases its share count by dividing its existing shares. The most recent split took place on September 11, 2023 with a ratio of 1:100. Throughout its history, the company has undergone 2 stock splits. Below, we delve deeper into this history, highlighting past financial strategies.
